Navigation Links
InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
Date:11/4/2009

BRISBANE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.

"IPF is a rapidly and uniformly fatal disease. Sadly, there are no medicines approved for the approximately 100,000 Americans who suffer from this terrible disease," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "InterMune has dedicated almost ten years to the development of new medicines for patients with IPF. We are very proud to have submitted the first NDA ever submitted to the FDA for a medicine to treat IPF patients."

About Pirfenidone

Preclinical and in-vitro evidence had shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. Results from three adequate and well-controlled Phase 3 studies have shown evidence of a treatment effect in IPF patients and the compound has been safe and generally well tolerated, with side effects including photosensitivity rash and gastrointestinal symptoms.

InterMune licensed pirfenidone from Marnac, Inc. and its co-licensor, KDL GmbH, in 2002 and in 2007 purchased from Marnac and KDL the rights to sell the compound in the United States, Europe and other territories except in Japan, Taiwan and South Korea where rights to the molecule were licensed by Marnac and KDL to Shionogi & Co. Ltd. of Japan. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

<
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 - what are the ... http://www.reportlinker.com/p0578544/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021---what-are-the-revenue-prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic What are ...
... Inc. (NASDAQ: CALP ) today reported its financial ... quarter revenue increased to $38.3 million, or 32%, from $29.1 ... excludes the effects of acquisitions, divestitures and currency changes, grew ... a year-to-date basis).  Caliper reported a second quarter net loss ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 13Caliper Life Sciences Reports Second Quarter 2011 Results 2Caliper Life Sciences Reports Second Quarter 2011 Results 3Caliper Life Sciences Reports Second Quarter 2011 Results 4Caliper Life Sciences Reports Second Quarter 2011 Results 5Caliper Life Sciences Reports Second Quarter 2011 Results 6Caliper Life Sciences Reports Second Quarter 2011 Results 7Caliper Life Sciences Reports Second Quarter 2011 Results 8Caliper Life Sciences Reports Second Quarter 2011 Results 9Caliper Life Sciences Reports Second Quarter 2011 Results 10
(Date:7/31/2015)... and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. ... , Glancing out of the window, he recalled that his equipment was set up ... Street tower, he jumped out of bed. , The photo speaks for itself. Chatfield ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... “ Crack’em ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... make less mess while cooking. , Cooking can be a very messy experience, especially ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Make Less Mess while Cooking with Crack’em 2
... remove key cue to safety; group seeks legislative help ... be nearly silent, hybrid cars pose a serious threat of ... the American Council of the Blind, which is pushing the ... this danger. , "Traditionally, people who are blind or visually ...
... in Obesity and Weight Management ... ... Inc., the,pioneer in applying advanced technology to emulate a health coaching,session ... management,behavioral health, and medication adherence, is launching HealthMedia(R),Overcoming(TM) Binge Eating. This ...
... PITTSBURGH, July 21 Mylan Inc. (NYSE: ... Crookshank as vice president -,Investor Relations and as ... to Chief Financial Officer Edward J. Borkowski, Crookshank ... as for the,development and direction of activities that ...
... HUNTSVILLE, Ala., July 21 Health,Care Systems, Inc. ... the market leader in medication reconciliation solutions, has ... of the largest,locally owned not-for-profit hospitals in the ... serves as a teaching facility for The,University of ...
... for action from ICANN, US-based domain ... ... an,online pharmacy verification service, and KnujOn.com, an Internet spam and,criminality watchdog, ... illicit sale of anabolic steroids., Steroid abuse is part of ...
... future alternative to bypass surgery, researchers say , , FRIDAY, ... grown in mice the kind of functioning heart blood ... One ultimate goal is to replace some heart surgery ... in the body, providing a system of blood vessels ...
Cached Medicine News:Health News:Hybrid Cars Pose Risk to Blind, Visually Impaired 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 3Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 4Health News:Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Kids at Risk: Report Identifies 150 Websites Selling Anabolic Steroids 2Health News:Heart Blood Vessels Grown in the Lab 2
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: